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ABSTRACT
Transcriptional activation involves the ordered
recruitment of coactivators via direct interactions
between distinct binding domains and recognition
motifs. The p160/SRC/NCoA coactivator family com-
prises three members (NCoA-1, -2 and -3), which are
organized in multiprotein coactivator complexes.
We had identified the PAS-B domain of NCoA-1 as
an LXXLL motif binding domain. Here we show
that NCoA family members are able to interact with
other full-length NCoA proteins via their PAS-B
domain and they specifically interact with the CBP-
interaction domain (CID/AD1) of NCoA-1. Peptide
competition, binding experiments and mutagenesis
of LXXLL motifs point at distinct binding motif
specificities of the NCoA PAS-B domains. NMR
studies of different NCoA-1-PAS-B/LXXLL peptide
complexes revealed similar although not identical
binding sites for the CID/AD1 and STAT6 transacti-
vation domain LXXLL motifs. In mechanistic studies,
wefoundthatoverexpressionofthePAS-Bdomainis
able to disturb the binding of NCoA-1 to CBP in cells
and that a CID/AD1 peptide competes with STAT6
for NCoA-1 in vitro. Moreover, the expression of an
endogenous androgen receptor target gene is
affected by the overexpression of the NCoA-1 or
NCoA-3 PAS-B domains. Our study discloses a new,
complementary mechanism for the current model of
coactivator recruitment to target gene promoters.
INTRODUCTION
The recruitment of transcriptional coactivators to target
gene promoters and enhancers by transcription factors
is a highly dynamic, sequential and ordered process (1).
Recruited coactivators modify histones and other coacti-
vators, recruit secondary coactivators and function as
bridging factors to the general transcription machinery.
They are associated in multiprotein coactivator com-
plexes. The composition of these complexes, as a
consequence of association and dissociation of the
involved coactivators, is inﬂuenced by conformational
changes, e.g. after post-translational modiﬁcations.
Diﬀerent classes and families of coactivator proteins
contribute to these complex processes and thus aﬀect the
regulation of gene expression. The p160/SRC/NCoA
coactivator family contains three homologous members.
NCoA-1 (Nuclear receptor coactivator 1), also called
SRC-1, NCoA-2 also called SRC-2, TIF2 or GRIP1 and
NCoA-3, also called p/CIP, RAC3, ACTR, AIB1 or
TRAM-1 (2).
They were identiﬁed as transcriptional coactivators for
nuclear receptors and it has been shown that they are also
involved in transcriptional activation of several diﬀerent
transcription factors, like members of the STAT family
(3–5) or NFkB (6,7).
The function of NCoA proteins is the recruitment of
coactivators with histone acetyltransferase activity (HAT),
like p300, CBP and p/CAF and cofactors with histone
methyltransferase activity (HMT), like CARM1 and
PRMT1. In addition, NCoA-1 and NCoA-3 possess
weak intrinsic HAT activities at the C-terminal region
(8,9). The ability of the NCoA family members to interact
with and to coactivate the same nuclear receptors indicates
that they have redundant functions. Nevertheless several
publications and the diﬀerent phenotypes of generated
knockout mice suggest that they have also speciﬁc
functions (10).
The three NCoA family members share common
structural domains, which provide surfaces for interac-
tions with DNA-bound transcription factors and with
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centrally located nuclear receptor interaction domain
(NID) mediates the ligand-dependent direct interaction
with diﬀerent nuclear receptors. NCoAs thus coactivate
together with associated coactivators hormone-induced
transcription (11–13). Diverse groups of coactivators with
diﬀerent enzymatic activities are associated to and
recruited by NCoA proteins through the interaction with
two transcriptional activation domains, called AD1 and
AD2. AD1 is also called CBP-interaction domain (CID),
because it mediates the interaction with the general
coactivators p300/CBP (9,12,14,15). The second trans-
criptional activation domain (AD2) is located at the
C-terminus and is responsible for the interaction with the
histone methyltransferases CARM1 and PRMT1 (16,17).
NCoA proteins contain speciﬁc LXXLL motifs (where
L is leucine and X is any amino acid), which arrange the
interaction with nuclear receptors via the NID (three
motifs), as well as with p300/CBP through the CID/AD1
(two motifs). The a-helical LXXLL motif is a signature
sequence which was identiﬁed in several coactivators
(e.g. NCoA proteins, p300/CBP and RIP140) (11,12).
It mediates the ligand-dependent recruitment of these
proteins to nuclear receptors. Although LXXLL motifs
themselves are responsible and suﬃcient for LXXLL-
mediated interactions, also the ﬂanking amino acids are
important. They provide the speciﬁcity and aﬃnity of
these interactions and additional contacts to interaction
partners (18–20). Several reports could show that only the
ﬂanking amino- or carboxyterminal amino acids are
crucial for these interactions (18,21–25). Furthermore
many coactivators contain multiple LXXLL motifs, which
could allow cooperative interactions (26,27).
The most highly conserved region of NCoA proteins is
the aminoterminal bHLH (basic helix-loop-helix) domain
and PAS (Per/ARNT/Sim) domain region. In general
bHLH domains are known as dimerization and DNA
interaction surfaces for many transcription factors, while
PAS domains are known to be involved in protein–protein
interactions and contribute to the dimerization process
mediated by the bHLH domains (28–30). NCoA proteins
contain two PAS domain regions (PAS-A and PAS-B).
The function of the bHLH/PAS region of the NCoA
family members is still largely unknown. In previous
studies we found that the PAS-B domain of NCoA-1
binds to an LXXLL motif in the transactivation domain
of STAT6. This interaction is essential for STAT6-
mediated transactivation (3,4). Thus our studies identiﬁed
the PAS-B domain as an LXXLL motif recognition
domain. The crystal structure of the NCoA-1 PAS-B
domain in complex with the STAT6 LXXLL motif
revealed several mechanistic diﬀerences in the LXXLL-
motif-binding mode compared with previous, nuclear-
receptor-based complexes (31). Speciﬁcally surface
complementarity between the hydrophobic faces of the
STAT6 LXXLL motif and of the NCoA-1 PAS-B domain
almost exclusively deﬁnes the binding speciﬁcity. Several
additional protein interactions of the aminoterminal
region including the PAS domain had been described for
NCoA proteins. NCoA-2 and NCoA-1 can contact the
coactivators CoCoA and GAC63 via the aminoterminal
region (32,33). Furthermore, it was postulated that NCoA
family members are able to dimerize through their
aminoterminal domains. First, gel ﬁltration experiments
showed an association of NCoA proteins in multiprotein
complexes (34). Later it could be demonstrated that a pair
of NCoA proteins is recruited to classical HRE- (hormone
responsive element) containing late gene promoters.
The bHLH/PAS domains are required for coactivation
of these genes (35). Nevertheless a direct interaction of
NCoA family members has not been detected in these
studies in vivo or in vitro.
Since the PAS-B domain of NCoA-1 is able to recognize
an LXXLL motif and NCoA proteins themselves exhibit
several LXXLL motifs in their amino acid sequence, we
hypothesized that the association of NCoA proteins can
be mediated through an interaction of the PAS-B domain
with the own LXXLL motifs. In this study we showed that
NCoA proteins are able to interact with each other
through the PAS-B domain and the CID/AD1. We
demonstrated that the three members of the NCoA
family use diﬀerent binding motifs in the CID/AD1.
Whereas NCoA-2 and NCoA-3 show similar binding
motif speciﬁcities, NCoA-1 binds to diﬀerent regions in
the CID/AD1. Chemical shift perturbation mapping
identiﬁed similar binding sites for the LXXLL motifs
of the STAT6-TAD and the CID/AD1 domain.
Furthermore, we were able to show that overexpression
of the PAS-B domain or competition with a CID/AD1
peptide interfered with the binding of CBP or STAT6,
respectively and aﬀected the transcriptional activation
mediated by nuclear receptors. Our data suggest a new
mechanism for coactivator complex formation and
recruitment of NCoA proteins to promoter sites.
MATERIALS AND METHODS
Cell cultureand transient transfection methods
293T and HeLa cells were grown in Dulbeccos minimal
essential medium (BioWhittacker) containing 10% fetal
calf serum. 293T cells were transiently transfected by the
standard calcium phosphate precipitation method. HeLa
cells were transiently transfected with ‘Superfect’ transfec-
tion reagent (Qiagen) according to the manufacturer’s
instructions. LnCap cells were cultured in RPMI 1640
medium (BioWhittacker) supplemented with 10% fetal
calf serum. Prior to hormone treatment cells were grown
in phenol red-free medium supplemented with 10%
charcoal-dextran-stripped fetal calf serum for at least
3 days. Cells were stimulated with 17b-estradiol (E2,
10
 7M) or dihydrotestosterone (DHT, 10
 7M) for 16h.
As a control cells were treated with vehicle (ethanol) in a
corresponding dilution.
Recombinant plasmids and constructs
The GST fusion constructs containing diﬀerent coactiva-
tor fragments (with amino acid numbers given) were
constructed by cloning the PCR ampliﬁed fragments in
frame in diﬀerent pGEX-expression vectors: hNCoA-1
(260–370); hNCoA-2 (268–379), and hNCoA-3 (265–375)
into the pGEX-5X-1 vector, hNCoA-1 (1–370), and
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taining a Tobacco-Etch-Virus (TEV) protease cleavage
site); hNCoA-1 (257–385) in the modiﬁed pET16b vector
containing a TEV protease cleavage site (31). The
expression vector pCS2+MT encoding for fusion proteins
with 6  Myc-tag and the construct of this plasmids
encoding rNCoA-1 (569–805), rNCoA-1 (804–1032) and
rNCoA-1 (1258–1442) were provided by L. Klein-Hitpass.
All expression vectors encoding for 6  Myc-tag fusions
of hNCoA-1 (1–370), hNCoA-1 (260–370), hNCoA-1
(901–970), hNCoA-1 (901–937), hNCoA-1 (938–970),
hNCoA-3 (265–375) and hNCoA-3 (1022–1092) as well
as the construct encoding for hSTAT6 (792–847) were
generated by inserting the corresponding PCR fragment in
frame into the pCS2+MT vector. Mutations were
introduced in the hNCoA-1 (901–970) construct by site-
directed mutagenesis according to the manufacturer’s
protocol (Stratagene). Expression vectors for mNCoA-1,
hNCoA-1 (pSG-SRC-1e), hNCoA-2 (pSG5-TIF2) and
hNCoA-3 (pcDNA3.1-AIB1) were kindly provided by
J. Torchia, M. Parker and H. Gronemeyer, respectively
and have been described previously (36,37). The expres-
sion vector for CFP (pECFP-C1) was purchased from
Clontech, BD Bioscience. The expression vector encoding
YFP-tagged rNCoA-1 (213–462) was generated by inser-
tion of the corresponding PCR fragment in frame into
the pEYFP-C1 vector (Clontech, BD Bioscience). The
expression vector containing FLAG-tagged residues
mCBP (2058–2130) was generated by introducing the
PCR fragment in frame before an internal ribosome entry
site (IRES) and GFP into pMX-FLAG-IRES-GFP
vector (a gift form T. Kitamura). The estrogen responsive
element (ERE) luciferase reporter construct (pGL2-ERE
TK-luc) was obtained from L. Klein-Hitpass. The expres-
sion vector for human estrogen receptor (pRSV-hER) and
the LacZ expression plasmid (pCH110) were described
previously (38,39). Lentiviral expression vectors contain-
ing residues hNCoA-1 (260–370) and hNCoA-3 (265–375)
were generated by PCR and insertion of fragments before
an IRES and GFP of pVIG (40). The packaging plasmid
used for lentivirus production sp2 and pHIT-G were
described previously (41,42). Insertion of all PCR
generated fragments was veriﬁed by digestion and DNA
sequence analysis.
Expression,purificationanddigestionofrecombinantproteins
Expression of the GST fusion proteins was performed in
Escherichia coli BL 21 (DE3) pLysS. The GST fusion
proteins were puriﬁed with glutathione Sepharose beads
(Amersham Biosciences). Cleavage of GST fusion proteins
expressed in pGEX-2-TEV vector was performed at room
temperature for 18h with TEV protease. GST-tag and
TEV protease were removed by glutathione Sepharose
and Ni-NTA Agarose beads (Qiagen).
GST pulldown experiments
Recombinant cDNAs in the pCS2+MT, pSG5 and
pcDNA3.1 expression plasmids were transcribed and
translated in vitro by reticulocyte lysate (Promega) in the
presence of [
35S]methionine according to manufacturer’s
instructions. GST pulldown assays were performed as
described previously (3). For competition experiments,
radioactive-labeled proteins were pre-incubated with
peptides for at least 15min. 10mg GST or GST fusion
proteins were used in the competition assays in the
absence or presence of corresponding peptides as indi-
cated. The amount and integrity of bound GST proteins
was estimated after SDS–PAGE in each experiment
by Coomassie staining. The binding of the in vitro
transcribed/translated proteins was detected by ﬂuorogra-
phy. Quantiﬁcation of bound radioactive-labeled proteins
was performed with a liquid scintillation analyzer
(Canberra Packard). Relative radioactivity (cpm, counts
per minute) was determined by normalizing against 10%
of the in vitro transcribed/translated proteins.
Peptides
Peptides representing the LXXLL motif 1 (KYSQTSHKL
VQLLTTTAEQQL), motif 2 (SLTERHKILHRLLQEG
SPSDI), motif 3 (KESKDHQLLRYLLDKDEKDLR),
motif 4 (EDQCISSQLDELLCPPTTVEG), motif 5 (EGR
NDEKALLEQLVSFLSGKD) of human NCoA-1
and the human STAT6 motif (LLPPTEQDLTKLLLEG
QGESG) were synthesized by the peptide synthe-
sis facility of the Department of NMR-based Structural
Biology at the Max-Planck-Institute for Biophysical
Chemistry.
NMRspectroscopy
NMR spectra were recorded from samples containing
0.5mM
15N- or
15N/
13C-labelled NCoA-1 PAS-B domain
fragment 257–385 that had been crystallized before in
complex with the STAT6 (794–814) peptide (31). NMR
experiments were carried out at 298K on DRX Bruker
Avance spectrometers equipped with z-gradient cryoprobe
and operating at 600 and 800MHz. All spectra were
processed using NMRPipe (43) and analyzed with Sparky
(http://www.cgl.ucsf.edu/home/sparky/) and CARA
(http://www.nmr.ch/).
1H-
15N HSQC experiments were
recorded on
15N-labelled NCoA-1 sample in its free form
and in presence of a 2-fold excess of peptide (STAT6
(794–814), motif 4 and motif 5 (Figure 3C)). NCoA-1
backbone resonance (
1H
N,
1H
a,
15N,
13C
a and
13C’)
assignment was carried out on a
15N/
13C-labelled sample
of the NCoA-1/STAT6 complex using conventional triple
resonance experiments: HNCA, HNCO, HN(CA)CO and
1H-
15N HSQC-NOESY. The chemical shift mapping of
the NCoA-1 binding site for the STAT6, motif 4 and motif
5 peptides was performed by comparing
1H-
15N HSQC
spectra of NCoA-1 in its free form and in complex with
the diﬀerent peptides. The amide chemical shift pertur-
bations (d) were calculated as d=|d
15N|/5+
|d
1H|(44).
Co-immunoprecipitation assays and western blotting
293T cells were transiently transfected with the corre-
sponding recombinant cDNA containing expression
vectors before co-immunoprecipitation was performed
as indicated. For LnCap cells, co-immunoprecipitation
was performed on the endogenous protein level.
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formed as described previously (3). The following
antibodies were used for co-immunoprecipitation: GFP
antibody (Clontech), SRC-1 antibody (M341, Santa
Cruz), SRC-2 antibody (OBT1796, AbD Serotec),
NCoA-3 antibody (M397, Santa Cruz), unspeciﬁc IgG
antibody (Santa Cruz) and anti-FLAG M2 Aﬃnity Gel
(Sigma). For western blotting, SRC-1 (1135, Biomol),
SRC-2 (OBT1796, AbD Serotec), NCoA-3 (M397,
Santa Cruz) or c-Myc antibody (Cell signaling) were
used. Visualization was performed with the ECL
plus western blotting Detection System (Amersham
Biosciences).
Luciferase assays
Before transfection, HeLa cells were grown for at least
3 days in hormone-free media. Cells were seeded in
12-well plates, and 1day after, transiently transfected
with 1.25mg luciferase reporter plasmid, the indicated
amount of expression vectors and 0.0125mgo fLacZ
expression plasmid for normalization. The total amount
of DNA was adjusted with the corresponding empty
vector. Twenty-four hours after transfection, cells
were treated with 10
 7M1 7 b-estradiol (E2) for 16h.
Cells were harvested and luciferase and b-galactosidase
activities were assayed according to the manufacturer’s
protocol (Promega). Luciferase activities were nor-
malized to the LacZ expression. The average of three
independent experiments with standard deviation is
shown.
Viral transduction and flowcytometry
For production of lentivirus, 293T cells were transiently
transfected with lentiviral vectors together with the
packaging plasmids sp2 and pHIT-G. Medium was
replaced after 16h and after an additional 24h, virus
supernatants were collected. LnCap cells (3 10
5) were
transduced in the presence of 4mg/ml polybrene (Sigma)
with a MOI (multiplicity of infection) of 0.2–2. After two
rounds of transduction, determination of lentiviral trans-
duction eﬃciency was performed by ﬂow cytometry on the
basis of GFP co-expression on the FACS Calibur and
FACS Scan (Beckton Dickinson) with Cell QuestPro
software (Beckton Dickinson).
Preparation ofRNA andreal time-PCR
Extraction of total cellular RNA was performed using
TriFast
TM (Peqlab) and Rneasy Mini Kit (Qiagen)
according to the manufacturer’s instructions. cDNA was
obtained by reverse transcription of 4mg of total cellular
RNA using Omniscript reverse transcriptase (Qiagen)
according to the manufacturer’s protocol. For quantiﬁca-
tion of speciﬁc transcripts, the i-Cycler MyiQ Single Color
Real-Time PCR Detection System (Biorad) and the
ABsolute QPCR SYBR Green Mix (Abgene) were used.
Ampliﬁcation of samples was performed in triplicates.
mRNA levels were normalized against endogenous 18S
mRNA. The following primers for the speciﬁc ampliﬁca-
tion of diﬀerent transcripts were used: 18S RNA:
50-CGGCTACCACATCCAAGGA-30;5 0-CCAATTACA
GGGCCTCGAAA-30 (40); PSA: 50-GGCAGCATTG
AACCAGAGGAG-30;5 0-GCATGAACTTGGTCAC
CTTCTG-30 (45); hNCoA-1 PAS-B domain: 50-TCA
GGGCAGAGAACCATCTTAT-30;5 0-CATGATGAAA
GGTTGCATGTCT-30; hNCoA-3 PAS-B domain:
50-ATGGTCCCAGAAACGTCACTAT-30;5 0-AAGGA
AGTGGGTTGAGACAAAG-30
RESULTS
Interaction ofNCoA proteins incells
Previous studies demonstrated that members of the
SRC/NCoA family can form heteromultimeric complexes
with each other (34). In addition, heterodimerization of
NCoA proteins was proposed as a mechanism for the
recruitment of distinct pairs of NCoAs to certain
promoters (35). In order to clarify how the interaction
of these coactivators takes place, complex formation of
NCoA family members was ﬁrst analyzed by co-immu-
noprecipitation experiments with whole cell lysates of
293T and LnCap cells. In both cell lines NCoA-3 could be
co-immunoprecipitated with NCoA-1 and NCoA-2
(Figure 1, upper and middle lanes) and vice versa
NCoA-1 and NCoA-2 co-precipitated with NCoA-3
(lower lanes). In contrast NCoA-1 showed no or only a
very weak co-immunoprecipitation with NCoA-2 (upper
and middle lanes). The control antibodies (IgG) showed
no precipitation at all. These experiments clearly demon-
strated an interaction of the endogenous NCoA coactiva-
tors in two diﬀerent cell lines but no interaction of
NCoA-1 and NCoA-2.
Figure 1. NCoA proteins interact in cells. Whole cell extracts of 293T
and LnCap cells were prepared and immunoprecipitation (IP) was
performed with an anti-NCoA-1-speciﬁc, an anti-NCoA-2-speciﬁc, an
anti-NCoA-3-speciﬁc or an unspeciﬁc antibody (IgG). All samples were
analyzed by SDS–PAGE and western blotting with speciﬁc antibodies
against NCoA-1, NCoA-2 or NCoA-3, vice versa to immunoprecipita-
tion. As a control 1% of the cell lysates were analyzed in parallel
(Input 1%).
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Our own studies on the coactivator function of NCoA-1 in
transcriptional regulation by STAT6 demonstrated that
the PAS-B domain of NCoA-1 recognizes an LXXLL
motif in the STAT6 transactivation domain (3,4,31). To
investigate if the PAS-B domains of NCoA family
members are able to interact with their own LXXLL
motifs, we used diﬀerent fragments of NCoA-1-spanning
regions with LXXLL motifs and as a control a fragment
of STAT6 containing the NCoA-1 interacting LXXLL
motif (Figure 2A) and analyzed the binding in GST
pulldown experiments. All GST fusion proteins of the
PAS-B domains of NCoA-1, NCoA-2 and NCoA-3
revealed a speciﬁc interaction with the construct contain-
ing two LXXLL motifs in the CID/AD1 in vitro
(Figure 2A). The other domains of NCoA-1 which also
contain LXXLL motifs showed almost no interaction with
PAS-B domain fusion proteins (NID) or only a weak
interaction with the transcriptional activation domain 2
(AD2) in the case of NCoA-1 and NCoA-3. No binding of
radioactive-labeled constructs to GST alone was detected.
In addition to the already described interaction of the
STAT6 construct with the PAS-B domain of NCoA-1,
also an interaction with the PAS-B domain of NCoA-3
could be observed. These results indicate that the NCoA
proteins are able to interact in vitro via their PAS-B
domain speciﬁcally with the CID/AD1, which contains
Figure 2. Interaction of NCoA proteins through the PAS-B domains and CID/AD1. (A) Schematic representation of NCoA-1, diﬀerent NCoA-1
constructs and the STAT6-TAD fragment. bHLH domain, PAS domain, NID [three LXXLL motifs (black bars)], CID/AD1 (two LXXLL motifs) and
AD2 (one LXXLL motif) are indicated. The STAT6 peptide comprises the NCoA-1 interacting LXXLL motif (black bar). The terminal amino acids of
each construct are shown. The NCoA-1 fragments representing diﬀerent regions containing LXXLL motifs were in vitro transcribed/translated and
[
35S]methionine-labeled. A STAT6 fragment which contains the NCoA-1 interacting LXXLL motif was used as a control. After incubation with GST
or GST fusion proteins of NCoA-1, NCoA-2 or NCoA-3 PAS-B domains, bound to glutathione Sepharose beads, proteins were eluted and analyzed by
SDS–PAGE and ﬂuorography. As an input control 10% of the radioactive-labeled proteins were analyzed in parallel. (B) Experiments were performed
with the radioactive-labeled full-length NCoA-1, NCoA-2 and NCoA-3 as described before. (C) 293T cells were transiently transfected with expression
vectors encoding either a YFP fusion protein of NCoA-1 aa 213–462, containing the PAS-B domain, or CFP and full-length NCoA-1 (each 3mg). Cell
extracts were prepared and immunoprecipitation (IP) was performed with an anti-GFP antibody, recognizing CFP and YFP. Proteins were analyzed by
SDS–PAGE and western blotting with an anti-NCoA-1 antibody. As a control 1% of the cell lysates were analyzed in parallel (Input 1%). (D) The
GST pulldown assay was performed with the GST fusion protein comprising the aminoterminal region of NCoA-1 (aa 1–370) and the [
35S]methionine-
labeled fragments of NCoA-1 containing the aminoterminal region or the CID/AD1 (aa 804–1032).
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PAS-B domain of NCoA-3 is also able to interact with the
STAT6 LXXLL motif.
We next tested whether the PAS-B domains of the
NCoA proteins are able to interact with the full-length
proteins of NCoA family members. All [
35S]-labeled full-
length NCoA proteins were bound by the PAS-B domains
of the diﬀerent NCoA family members in vitro
(Figure 2B). The NCoA-1 PAS-B domain showed a
stronger interaction with full-length NCoA-1 compared to
the interaction of the other NCoA proteins. Thus the
interaction of the PAS-B domain that we observed before
is not restricted to NCoA-1 and functions also for binding
of all three full-length coactivators, although obviously
with diﬀerent aﬃnities.
To investigate if the PAS-B domain of NCoA-1 is able
to bind full-length NCoA-1 also in vivo, co-immunopre-
cipitation experiments were carried out. 293T cells were
transiently co-transfected with an expression construct
encoding a YFP fusion protein of NCoA-1 comprising
amino acids 213–462 and a full-length NCoA-1.
Immunoprecipitation with an anti-GFP antibody
co-precipitated full-length NCoA-1 only when the YFP
fusion protein containing the PAS-B domain of NCoA-1
was co-transfected, thus supporting our in vitro interaction
studies, showing that the isolated PAS-B domain is
suﬃcient to bind full-length NCoA-1 (Figure 2C, left
panel). No precipitation was observed in the presence of
the CFP control.
Since the bHLH/PAS region in the aminoterminus of
NCoA family members was suggested to be a dimerization
domain which should mediate multimerization of NCoA
proteins (29,46) we next compared the interaction
potential of the aminoterminus and the CID/AD1.
Whereas the CID/AD1 (aa 804–1032) strongly bound to
the GST fusion protein of NCoA-1 comprising amino
acids 1–370 (Figure 2D, right panel) we could not detect
an interaction of the aminoterminal region with itself
(Figure 2D, left panel). Thus these results support our
hypothesis that complex formation of NCoA family
members is attributed to an interaction between the
PAS-B domain and the CID/AD1, but not to a dimeriza-
tion of NCoA proteins through the aminoterminal bHLH/
PAS domain region.
Distinct functions of theLXXLL motifs in theinteraction
ofthe NCoA PAS-Bwith theCID/AD1 domain
The fragment which we tested for interaction with the
PAS-B domain of NCoA proteins contains two LXXLL
motifs and the complete region which mediates the
interaction with CBP (amino acids 926–960; Figure 3A)
(47). We wondered whether NCoA proteins and CBP bind
to the same motifs, overlapping motifs or diﬀerent motifs
in the CID/AD1. To ascertain this, we ﬁrst narrowed
down the CID/AD1 fragment to a region which contains
the known binding motifs and then analyzed distinct parts
of the restricted region. A minimal fragment comprising
amino acids 901–970, which contains both LXXLL motifs
and the minimal CBP-interaction motif was tested for
interaction with the PAS-B domains of all three NCoA
family members and a fusion protein containing the
NCoA-1 interaction surface of CBP, which contains the
CBP amino acids 2058–2130. All three NCoA PAS-B
domain constructs and the CBP fusion protein strongly
interacted with the restricted CID/AD1 spanning amino
acids 901–970 (Figure 3B).
Two fragments comprising the amino acids 901–937
and 938–970 of the CID/AD1 (Figure 3A) were used to
further analyze the binding speciﬁcity of the diﬀerent
NCoA family members and CBP. These fragments
contain either the aminoterminal region with both
LXXLL motifs or the carboxyterminal part without an
LXXLL motif. The PAS-B domain of NCoA-1 interacts
with the aminoterminal region at a level that was
comparable to the interaction with the intact fragment
(Figure 3B). In contrast, the PAS-B domains of NCoA-2
and NCoA-3 showed a strongly reduced interaction. The
carboxyterminal fragment (aa 938–970) interacted only
with the NCoA-1 PAS-B domain. However this interac-
tion was much weaker compared to the interaction of the
aminoterminal part (aa 901–937) or the complete region
(aa 901–970) (Figure 3B). The CBP-GST fusion interacted
with none of the shortened fragments.
To further examine the diﬀerence between NCoA-1 and
NCoA-3 we repeated the experiment with a fragment
representing the minimal CID/AD1 region of NCoA-3
(aa 1022–1092) (Figure 3A). Only the NCoA-1 PAS-B
domain and the CBP construct strongly bound to the
CID/AD1 fragment of NCoA-3 (Figure 3B). The GST
PAS-B domain fusions of NCoA-2 and NCoA-3 showed
no interaction at all. Taken together these results indicate
that the PAS-B domains of the NCoA family members
and CBP recognize distinct binding sites in the CID/AD1.
To examine the contribution of individual LXXLL
motifs to the interaction we tested whether a single
LXXLL motif-containing peptide is able to compete with
the interaction between the PAS-B domains of NCoA-1,
NCoA-2 and NCoA-3 and the CID/AD1 of NCoA-1.
Peptides were designed to cover each LXXLL motif with
the neighboring eight amino acids at both sites in the CID/
AD1 of NCoA-1 (motif 4 and motif 5, Figure 3C). As a
control we used a peptide that contains the LXXLL motif
of STAT6, which was shown to abolish the interaction
between NCoA-1 and the STAT6 transactivation domain
(4). The peptide representing the LXXLL motif 4 and
motif 5 blocked almost completely the interaction of the
NCoA-1 PAS-B domain with the CID/AD1at the highest
concentration (280mM, Figure 3C, lane 4 and 7). But also
lower concentrations showed inhibitory eﬀects (lanes 5
and 8). The peptide representing the STAT6 motif blocked
the interaction only at the highest concentration (lane 10).
In contrast to the interaction of the NCoA-1 PAS-B
domain, the interaction of the NCoA-2 and NCoA-3
PAS-B domain was only slightly aﬀected in competition
experiments at the highest concentration with LXXLL
motif 5 (lanes 19 and 31). Also the STAT6 motif did not
inhibit these interactions eﬃciently (lanes 22–24 and
34–36). To test whether the observed competition eﬀects
are speciﬁc for the LXXLL motifs of the CID/AD1, we
performed similar experiments with peptides representing
the three LXXLL motifs located in the NID domain of
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senting motifs 1, 2 and 3 showed no inhibitory eﬀect on
the binding of the CID/AD1 to the PAS-B domains of
NCoA-1 or NCoA-2 and NCoA-3at any given concen-
tration. In summary, our results indicate that the PAS-B
domains of the NCoA coactivators recognize speciﬁc
motifs in the CID/AD1, which comprise both LXXLL
motifs, but obviously also diﬀerent binding structures.
The amino acid context of the LXXLL motifs seems to
deﬁne the binding speciﬁcity. In addition, diﬀerent
interaction modes might be used by the PAS-B domains
of the diﬀerent NCoA family members.
To examine directly the importance of each LXXLL
motif for the NCoA PAS-B-CID/AD1 interaction, we
mutated the sequence of the LXXLL motifs. We replaced
leucine 913 and 916 of motif 4 (MutM4), leucine 933 and
936 of motif 5 (MutM5) or all four leucine residues
together (MutM4+5) with alanine in the restricted region
of the NCoA-1 CID/AD1 (aa 901–970) (Figure 3D). The
interaction of the NCoA-1 PAS-B domain with the
CID/AD1 was not aﬀected through the point mutations
in LXXLL motif 4 and only slightly aﬀected through the
mutation of motif 5 or both motifs (Figure 3E and F).
In contrast the interactions of the PAS-B domains of
NCoA-2 and NCoA-3 were clearly reduced through
mutation of motif 4 and strongly inhibited through
mutation of motif 5. Mutation of both motifs nearly
abolished the interaction. The binding of the CBP fusion
protein to the CID/AD1 fragment was nearly not aﬀected
by point mutations in LXXLL motif 4, whereas mutations
in motif 5 or both motifs strongly diminish the contact.
This was expected since only motif 5 is part of the CBP
binding region (Figure 3A). These results underline that
the LXXLL motifs obviously act diﬀerentially in the
coactivator interactions. Both LXXLL motifs contribute
to the interaction of the PAS-B domains of NCoA-2 and
NCoA-3, although motif 5 seems to have the more
important function. The binding of CBP requires only
motif 5 and the leucines in both motifs are obviously not
essential for the interaction of the NCoA-1 PAS-B
domain.
To further probe the means through which the NCoA-1
PAS-B domain recognizes the diﬀerent LXXLL motifs, we
performed
1H-
15N HSQC monitored chemical shift
mapping upon STAT6, motif 4 and motif 5 peptide
binding. We recorded and compared
1H-
15N HSQC
spectra of the
15N-labeled PAS-B domain protein in
presence of saturating concentrations of the motif 4 and 5
peptides (Figure 3G) as well as the STAT6 peptide. We
were able to assign 88% of the 117 observable resonances
on the
1H-
15N HSQC spectrum (out of 124 expected). The
same level of assignment was obtained for the
1H-
15N
HSQC spectra of the diﬀerent NCoA-1/peptide com-
plexes. All three complexes exhibit strong chemical shift
perturbations for the same parts of the protein, namely the
bB strand and aC, aD helices (Figure 3G and
Supplementary Data 3). These secondary structure ele-
ments form part of the hydrophobic cleft in which the
STAT6 peptide binds in the NCoA-1/STAT6 complex
X-ray structure (31). Other signiﬁcant chemical shift
perturbations were observed on other parts of the protein,
especially upon STAT6 peptide binding. These shifts are
probably generated by long-range perturbations. Upon
binding of each of the three peptides, HN resonances of
the same set of NCoA-1 residues are aﬀected with a
similar d pattern. This observation reveals that all three
peptides bind to the same site, namely the hydrophobic
cleft as observed in the NCoA-1/STAT6 X-ray structure.
Nevertheless a closer inspection of the d values shows
also diﬀerences between the d patterns of the three
peptides (Supplementary Data 2). The motif 4 and motif 5
peptides generate very similar chemical shift perturbation
patterns upon binding whereas the chemical shift pertur-
bations generated upon STAT6 binding show clear
diﬀerences.
Using isothermal titration calorimetry (ITC) the Kd of
the STAT6 peptide for binding to the NCoA-1 PAS-B
domain has been determined before to be about 1mM (31).
Trials to measure the Kd values of the motif 4 and motif 5
peptides for binding to the NCoA-1 PAS-B domain with
ITC and ﬂuorescence titration failed. With both methods
interpretable saturation curves could not be obtained.
Measurement of the aﬃnities of the three peptides using
chemical shift perturbations of aﬀected residues in the
NCoA-1 PAS-B domain were also not feasible due to an
exchange rate in the fast to intermediate timescale (data
not shown). Thus a direct comparison of the aﬃnities of
the three motifs to the NCoA-1 PAS-B domain was not
possible. However, we expect from these approaches, that
motifs 4 and 5 have an at least 10–50-fold lower aﬃnity
compared to the STAT6 motif. We assume that both
LXXLL motifs and amino acids next to the motifs of the
CID/AD1 are particularly important for higher aﬃnity
binding. This would be in agreement with our results from
the qualitative analysis of the binding (Figure 3).
Competition between the interaction domains ofNCoA-1,
CBPand STAT6
To analyze the inﬂuence of the identiﬁed interactions on
the formation and composition of coactivator complexes,
we ﬁrst examined if the interaction of the PAS-B domain
and the CID/AD1 is able to aﬀect the interaction of
NCoA-1 with the coactivator CBP. This could be very
important for the recruitment of coactivator complexes
and transcriptional activation mediated by transcription
factors like the nuclear receptors. For this purpose 293T
cells were transiently transfected with an expression
construct encoding a FLAG-tagged CBP fragment
(aa 2058–2130) comprising the region which is necessary
for the interaction with NCoA-1 (47) together with an
expression vector of the Myc-tagged CID/AD1 fragment
of NCoA-1 (aa 804–1032). To test for competition, the
cells were additionally transfected with a 30-fold excess of
a construct encoding the PAS-B domain of NCoA-1
(aa 213–462). Co-immunoprecipitation experiments were
performed with a speciﬁc antibody recognizing the
FLAG-tag and analyzed by SDS–PAGE and western
blotting with an anti-Myc-tag speciﬁc antibody recogniz-
ing the fragment of the NCoA-1 CID/AD1. The fragment
of the CID/AD1 of NCoA-1 (aa 804–1032) could be
co-immunoprecipitated with the FLAG-tagged CBP
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Figure 3. LXXLL motifs diﬀerentially contribute to the interaction of the PAS-B domains and the CID/AD1 of NCoA-1. (A) Sequence alignment of
the fragments in the CID/AD1 of NCoA-1 and NCoA-3. LXXLL motifs are printed in bold. The regions of NCoA-1 and NCoA-3 which mediate
the interaction with CBP are indicated in boxes (NCoA-1 aa 926–960 and NCoA-3 aa 1045–1091). Terminal amino acids of each construct are
shown. Sequences of NCoA-1 and NCoA-3 correspond to the protein ID’s AAI11534 and AAC51677, respectively. (B) Fragments of NCoA-1
comprising amino acids 901–970, 901–937 or 938–970 and NCoA-3 comprising amino acids 1022–1092 of the CID/AD1 were in vitro transcribed/
translated and [
35S]methionine-labeled. The fragments were incubated with GST alone or GST fusion proteins of the PAS-B domains of all three
NCoA family members or a fusion protein of the CBP NCoA interacting region (aa 2058–2130) bound to glutathione Sepharose. Precipitated
proteins were analyzed by SDS–PAGE and ﬂuorography. 10% of radioactive-labeled material used for interaction assays was analyzed in parallel
(Input). (C) Structure of NCoA-1. Diﬀerent functional domains (grey boxes) and LXXLL motifs (black bars) are indicated. Peptides derived from
the CID/AD1 used in competition experiments are shown. The sequences representing LXXLL motif 4 and motif 5 are printed in bold. GST
pulldown assays were performed as described in B, with the NCoA PAS-B domains and the [
35S]methionine-labeled fragment of the NCoA-1
CID/AD1 in absence or presence of 280, 28 or 2.8mM of each peptide. (D) Schematic representation of the NCoA-1 CID/AD1 sequence. LXXLL
motifs 4 and 5 are printed in bold. Point mutations of leucines to alanines are depicted for motif 4 (MutM4), motif 5 (MutM5) and both motifs
(MutM4+5). (E) Experiments were performed as described in B with the radioactive-labeled fragments containing residues 901–970 of wild type or
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(Figure 4A, lane 4). There was no immunoprecipiation
with the FLAG-tag control (lane 2). Co-transfection of
the YFP fusion protein of the NCoA-1 PAS-B domain led
to a strong and almost complete inhibition of the
interaction between the CID/AD1 and the CBP fragment
(lane 6), whereas overexpression of CFP showed no eﬀect
(lane 4). This experiment demonstrated that overexpres-
sion of the NCoA-1 PAS-B domain is able to disturb the
interaction of the NCoA-1 CID/AD1 with CBP.
Since NCoA-1 is recruited by STAT6 via a direct
interaction of its PAS-B domain with the LXXLL motif in
the STAT6-TAD we wondered whether the binding of the
CID/AD1 is able to inhibit this interaction. In vitro
competition assays with bacterially expressed NCoA-1
CID/AD1 peptides (aa 901–970) and GST fusion proteins
of the NCoA-1 PAS-B domain and radioactive-labeled
STAT6 fragment (aa 792–846) were performed. The
interaction of the NCoA-1 PAS-B domain with the
STAT6-TAD fragment was diminished in the presence
of the CID/AD1 peptide (Figure 4B). The quantitative
analysis revealed a more than 50% reduction of the
interaction (Figure 4C). This result indicates that the
interaction of the PAS-B domain and the CID/AD1 could
not only aﬀect the binding of the coactivator CBP, but is
also able to inﬂuence the interaction and recruitment of
NCoA-1 by transcription factors like STAT6.
Different effects ofthe PAS-Bdomains onthe
transcriptional activation by nuclear receptors
Since overexpression of the PAS-B domain aﬀects the
interaction of NCoA-1 with CBP as shown before, we
investigated the role of the PAS-B domain-CID/AD1
interaction on the formation of coactivator complexes in
transcriptional activation. Particularly the postulated
recruitment of NCoA protein pairs to certain target gene
promoters of nuclear receptors could be concerned (35).
We ﬁrst analyzed whether the overexpression of the
isolated PAS-B domain and the CID/AD1 might inﬂuence
transcriptional activation by the estrogen receptor in
luciferase reporter assays. Co-expression of increasing
amounts of the NCoA-1 PAS-B domain (aa 260–370) had
no eﬀect on the transcriptional activation mediated by the
estrogen receptor in comparison to the control
(Figure 5A). Only a slight decrease in transactivation
could be observed with the fragment of the PAS-B domain
of NCoA-3 (aa 265–375). The CID/AD1 fragment (aa
804–1032) strongly inhibited the estrogen-dependent
transactivation, even at the lowest amount (50ng). These
results suggest that interactions via the CID/AD1 are
more essential for the recruitment of coactivator com-
plexes than the PAS-B domain in luciferase reporter
assays with the used promoter construct.
The comparably low eﬀects of the PAS-B domains that
we observed in luciferase reporter assays could be a result
of the diﬀerential recruitment of single or pairs of NCoA
proteins to certain promoters. Previous studies postulated
that pairs of NCoA-1 and NCoA-3 or NCoA-2 and
NCoA-3 are recruited to the promoter of the PSA
(prostate speciﬁc antigen) gene, which is a natural target
gene of the androgen receptor (AR) in LnCap prostate
carcinoma cells (35). We therefore examined next whether
overexpression of the PAS-B domains inﬂuences the
expression of PSA. For this we stably expressed the
PAS-B domains of NCoA-1 (aa 260–370) or NCoA-3
(aa 265–375), corresponding to the fragments used in the
reporter assays, by lentiviral transduction in the LnCap
cells. As a control, cells were transduced with the empty
vector (pVIG-Flag). The transduction eﬃciency was
conﬁrmed by FACS analysis on the basis of GFP
co-expression, and overexpression of the PAS-B domain
fragments was measured by quantitative RT-PCR.
Expression of PSA was measured by quantitative
RT-PCR in transduced LnCap cells grown in the absence
of androgen for at least 3 days, followed by treatment with
DHT for 16h (Figure 5B). Overexpression of the PAS-B
domains of NCoA-1 and NCoA-3 had contrary con-
sequences on the activation of the PSA gene. Whereas the
overexpression of the PAS-B domain of NCoA-1 (pVIG-
Flag-NCoA-1 aa 260–370) enhanced expression of PSA,
overexpression of the NCoA-3 PAS-B domain (pVIG-
Flag-NCoA-3 aa 265–375) reduced PSA expression. The
eﬀects on the expression of PSA were conﬁrmed with
independently transduced LnCap cells (data not shown).
Our results indicate that interactions via the PAS-B
domains of both NCoA family members NCoA-1 and
NCoA-3 are involved in the transcriptional regulation of
an endogenous AR target gene that had been postulated
to be dependent on the recruitment of two NCoA
proteins.
DISCUSSION
The NCoA protein family of coactivators mediates many
diﬀerent interactions with transcription factors and other
coactivators essential for transcriptional regulation.
Previous studies postulated that NCoA proteins are
associated in high molecular weight complexes (34) and
that dimerization of NCoA proteins is involved in their
recruitment to speciﬁc nuclear receptor target gene
promoters (35).
We demonstrated here that the PAS-B domains of all
NCoA family members alone are suﬃcient to interact with
all full-length NCoA proteins (Figure 2B). These results
clearly indicate that the PAS-B domain is not only able to
mediate the interaction with STAT6 as we had shown
before (4), but also allows the assembly with members of
mutant (MutM4, MutM5 or MutM4+5) NCoA-1. (F) Quantiﬁcation of bound radioactive-labeled fragments of wild type or mutant NCoA-1 CID/
AD1 (aa 901–970) to GST and GST fusion proteins. Relative radioactivity (cpm; counts per minute) was determined by normalization against an
aliquot representing 10% of the radioactive-labeled material. The average of three independent experiments with standard deviation is shown.
(G) Chemical shift perturbation plot on NCoA-1 sequence upon peptides binding.
1H-
15N HSQC titration data for the addition of LXXLL peptides
to the
15N -NCoA-1 PAS-B domain d values (calculated as described in Materials and Methods) generated upon motif 4 (blue bars), motif 5 (red
bars) and STAT6 peptide (green bars) binding are plotted against the NCoA-1 PAS-B domain sequence.
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domain might therefore enable the homo- and hetero-
dimerization of diﬀerent pairs of NCoA proteins at certain
promoters, as it has been suggested for the co-recruitment
of NCoA-3 and -1 or NCoA-3 and -2 to estrogen receptor
and androgen receptor regulated target gene promoters
(35). In contrast to NCoA-3, NCoA-2 was not able to
interact with NCoA-1, although it could interact with
NCoA-3 (Figure 1). This result adds an additional level of
complexity to the interaction of NCoA proteins which
might be regulated by post-translational modiﬁcation of
the full-length proteins in cells.
The PAS-B domains of all NCoA proteins bind to the
NCoA-1 CID/AD1 region which contains two LXXLL
motifs, but not to the NID with three LXXLL motifs or
the transcriptional activation domain 2 (AD2) with one
LXXLL motif. This indicates that there is a functional
redundancy of the NCoA coactivators, because all three
NCoA proteins are able to interact with each other
through the same domains. We were not able to show an
intermolecular interaction mediated through the amino-
terminal bHLH/PAS domains as postulated in previous
studies (29) (Figure 2D). Therefore our results suggest
that the described complex formation and association of
NCoA family members (34,35) is mediated by the
interaction of the PAS-B domain and the CID/AD1 and
not by the dimerization through the bHLH and PAS
domains. This is in contrast to other members of the
bHLH/PAS family of proteins, like AhR and ARNT
(30,48,49), which show dimerization through the bHLH/
PAS domains. However there are already examples of
bHLH/PAS protein interactions described, like the inter-
action of NCoA-1 with AhR, ARNT or HIF1a (50–52), in
which the binding is not mediated through the association
of both bHLH/PAS domain regions.
Although all NCoA proteins are able to bind via their
PAS-B domain to the CID/AD1 of NCoA-1, only the
NCoA-1 PAS-B domain can interact with the CID/AD1
of NCoA-3 (Figure 3B). This indicates that the PAS-B
domains of NCoA-2 and NCoA-3 might have diﬀerent
binding speciﬁcities compared to the PAS-B domain of
NCoA-1, which obviously uses diﬀerent binding sites in
the CID/AD1. Binding assays with the amino- and
carboxyterminal fragments of the CID/AD1 (Figure 3B)
and competition assays with peptides representing the
single LXXLL motifs (Figure 3C) demonstrate that both
LXXLL motifs are important for the interaction, but with
diﬀerent impact. In addition, the carboxyterminal frag-
ment of the CID/AD1 (aa 938–970), which contains
no LXXLL motifs, obviously binds independently and
speciﬁcally to the PAS-B domain of NCoA-1. This
indicates that the NCoA-1 PAS-B domain apparently
has several contact sites within the CID/AD1 region.
Our results also demonstrate that an eﬃcient interaction
of the NCoA-2 and NCoA-3 PAS-B domains requires an
intact CID/AD1 region comprising both the aminoterm-
inal region with the LXXLL motifs and the carboxyterm-
inal region. Splitting of this region strongly reduced the
binding to the aminoterminal region and rather abolished
the binding to the carboxyterminal fragment. This is
in contrast to the NCoA-1 PAS-B domain (Figure 3B).
Figure 4. Overexpression of the NCoA PAS-B domain or competition
with the CID/AD1 inhibits contact of NCoA-1 to CBP or the STAT6-
TAD. (A) 293T cells were transiently transfected with expression
vectors encoding a FLAG-tagged CBP fragment (aa 2058–2130) or the
empty FLAG-tag vector (pMX-FLAG) (each 1mg), a 6  Myc-tagged
CID/AD1 fragment of NCoA-1 (aa 804–1032) (0,1mg) along with a
vector containing a YFP fusion protein encoding NCoA-1 aa 213–462
or CFP as a control (each 3mg). Whole cell extracts were prepared and
co-immunoprecipitation was performed with a speciﬁc anti-FLAG-tag
antibody. Precipitated proteins were analyzed by SDS–PAGE, followed
by western blotting with an anti-Myc-tag antibody. Aliquots corre-
sponding to 1% of the used cell lysates were analyzed in parallel
(Input 1%). (B) GST or the GST fusion protein of NCoA-1 PAS-B
domain (aa 260–370) were bound to glutathione Sepharose beads and
incubated with a [
35S]methionine-labeled fragment of the STAT6-TAD
(aa 792–847) in absence or presence of 45mM of a puriﬁed NCoA-1
CID/AD1 peptide (aa 901–970). After washing and elution, precipitated
proteins were analyzed by SDS–PAGE and ﬂuorography. The CID/
AD1 fragment was bacterially expressed, digested and puriﬁed as
described in Materials and Methods. An aliquot representing 10% of
the in vitro transcribed/translated fragment was analyzed in parallel
(Input). A quarter of each binding reaction was separately analyzed by
SDS–PAGE and Coomassie staining in order to prove same amounts of
GST or GST fusion proteins. (C) Quantiﬁcation of bound STAT6-TAD
fragment to GST or GST fusion protein of the NCoA-1 PAS-B domain in
absence or presence of the CID/AD1 peptide. The relative radioactivity
(cpm; counts per minute) was determined by normalization against 10%
of the in vitro transcribed/translated protein. The average of three
independent experiments with standard deviation is shown.
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mutants of the LXXLL motifs in the CID/AD1 domain
conﬁrmed our assumption that both motifs contribute to
the binding of the NCoA-2 and NCoA-3 PAS-B domains
(Figure 3D–F). These studies also disclose that the
leucines in both LXXLL motifs of the CID/AD1 are
obviously not essential for the binding of the NCoA-1
PAS-B domain. This was a surprise because peptides
representing speciﬁcally these motifs inhibited the binding
of the NCoA-1 PAS-B domain to the CID/AD1
signiﬁcantly (Figure 3C). Thus we assume that other
amino acids than the leucines in these motifs provide the
contact to the NCoA-1 PAS-B domain. Or the carboxy-
terminal part of the CID/AD1 (aa 938–970) which weakly
interacts independently with the NCoA-1 PAS-B domain
(Figure 3B) stabilizes the binding of the mutants. All these
results conﬁrmed that the PAS-B domains of NCoA-2 and
NCoA-3 might have diﬀerent binding motif speciﬁcities
for the CID/AD1 in comparison to the NCoA-1 PAS-B
domain.
Preliminary NMR studies of the diﬀerent NCoA-
1-PAS-B/LXXLL peptide complexes, which were per-
formed to get a closer insight into the binding mode of
the LXXLL motifs to the NCoA-1 PAS-B domain,
revealed similar strong chemical shift perturbations for
all three complexes (Figure 3G). The same parts of
the PAS-B hydrophobic cleft, previously shown to
represent the binding side of the STAT6 peptide (31)
(Supplementary Data 3) were aﬀected upon binding of the
STAT6, motif 4 and motif 5 peptides providing an
unambiguous evidence that all three peptides bind to the
same site in solution. Further NMR studies which will
include the PAS-B domain of NCoA-3 as well as peptide
fragments representing both LXXLL motifs together with
the carboxyterminal part of the CID/AD1 will be essential
to disclose the diﬀerences in the binding mode and to
understand how the selectivity of the NCoA PAS-B
domains is achieved. These studies will be conducted in
the future.
The binding sites of the PAS-B domains overlap with
the binding site of CBP [NCoA-1 aa 926–960, (47)]. This is
supported by several ﬁndings. First, the CBP fragment,
containing the NCoA-1 interaction site showed almost the
same binding characteristics with the amino- and carboxy-
terminal fragments of the NCoA-1 CID/AD1 as the
NCoA-2 or NCoA-3 PAS-B domains did (Figure 3B).
The NCoA-1 PAS-B domain and the CBP region inter-
acted similar with the NCoA-3 CID/AD1 (Figure 3B).
Figure 5. Overexpression of the NCoA-1 and NCoA-3 PAS-B domains or a CID/AD1 fragment diﬀerentially aﬀects transcriptional activation by
nuclear receptors. (A) Schematic structure of NCoA-1 and diﬀerent NCoA protein constructs. Functional and structural domains of NCoA-1 are
depicted. The bHLH domain, PAS domain, NID, CID/AD1, AD2 and corresponding LXXLL motifs (black bars) are indicated. Terminal amino
acids of each construct are shown. HeLa cells were transfected with expression vectors for the luciferase reporter plasmid pGL2-ERE TK-luc
(1.25mg), the estrogen receptor (12.5ng) and the LacZ expression plasmid (12.5ng) along with expression plasmids for the PAS-B domains of NCoA-
1 (aa 260–370) or NCoA-3 (aa 265–375) or the NCoA-1 CID/AD1 (aa 804–1032) (each 50, 100 or 200ng) or the empty expression vector (200ng;
contr.) as indicated. Total amount of DNA was adjusted with the empty expression vector. Transfected cells were grown for at least 3 days without
17b-estradiol (E2) and then treated (black bars) or not treated (unstimulated; white bars) with E2 (10
–7M) for 16h. Cell extracts were prepared and
luciferase and b-galactosidase activities were determined. Luciferase activities were normalized to the LacZ expression. The average of three
independent experiments   standard deviation is shown. (B) LnCap cells were transduced with lentiviruses encoding the PAS-B domain of NCoA-1
(pVIG-Flag-NCoA-1 aa 260–370), NCoA-3 (pVIG-Flag-NCoA-3 aa 265–375) or the empty vector (pVIG-Flag) alone. The transduction eﬃciency for
the PAS-B domain of NCoA-1 (88–95%), NCoA-3 (32–54%) and the empty vector (92–95%) was conﬁrmed by FACS analysis on the basis of GFP
co-expression. Cells were grown for at least 3 days in absence of androgen, followed by treatment (dark grey bars) or no treatment [EtOH (vehicle;
ethanol), light grey bars] with dihydrotestosterone (DHT; 100 nM) for 16h. Total cellular RNA of transduced cells was extracted and transcribed to
cDNA. Relative PSA (prostate speciﬁc antigen) expression was quantiﬁed via quantitative RT-PCR using speciﬁc primers. mRNA levels of PSA were
normalized against endogenous 18S mRNA. A 12-fold overexpression of the NCoA-1 PAS-B domain and a 2-fold overexpression of the NCoA-3
PAS-B versus endogenous NCoA-1 or NCoA-3, respectively were also determined via quantitative RT-PCR with speciﬁc primers. A representative
result of three independent transduction of LnCap cells is shown with standard derivation from triplicate RT-PCR measurements.
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CID/AD1 region aﬀected the binding of the NCoA-2 and
NCoA-3 PAS domains to nearly the same degree as the
binding of the CBP fragment (Figure 3D–F). The
structure analysis of the CBP NCoA interaction fragment
in complex with the CID/AD1 of NCoA-3 (ACTR;
Activator of thyroid and retinoic acid receptors) revealed
that the CID/AD1 has little intrinsic structure but appears
to undergo induced folding in complex with CBP (53,54).
A recent report, which compared this structure with the
structure of the CBP NCoA interaction fragment in
complex with the NCoA-1 CID/AD1 found that the CID/
AD1 adopt distinct conformations in both complexes (55).
These studies suggest that the NCoA CID/AD1 domains
have a degree of conformational ﬂexibility, which might
facilitate the rapid dissociation of complexes. It will
therefore be interesting to see if the CID/AD1 adopts
diﬀerent conformation in the complex with CBP and the
PAS-B domain.
We analyzed whether CBP and NCoA-1 compete for
binding to the CID/AD1 region, which should aﬀect the
formation and recruitment of coactivator complexes and
thus transcriptional activation. Overexpression of the
PAS-B domain is able to inhibit the binding of the CBP
NCoA interaction region to the CID/AD1 fragment in
cells as shown by co-immunoprecipitation experiments
(Figure 4A). The CID/AD1 fragment can also inhibit the
recruitment of the NCoA-1 PAS-B domain by the STAT6-
TAD in vitro (Figure 4B and C) indicating that binding of
diﬀerent proteins to the same subdomain can aﬀect the
coactivator assembly. The ordered recruitment of coacti-
vators during the transcriptional activation process might
allow such competitive interactions of diﬀerent partners,
since it could be regulated by allosteric changes induced
within interacting partners (56). Multicomponent com-
plexes of the NCoA coactivators (57) are not static entities
but rather dynamic rearrangements that are related to
their particular roles during diﬀerent subreactions in
transcription (58).
Overexpression of the CID/AD1 domain strongly
reduced the estrogen-dependent transactivation after
transient transfection, indicating that the CID/AD1
fragment inhibits the interaction between NCoA proteins
and p300/CBP and thereby destabilizes the interaction
between p300/CBP and the estrogen receptor (47,59,60).
The marginal eﬀects that we observed for the PAS-B
domain fragments in transient assays might result from
the promoter context dependent function of coactivators.
The promoter region of the luciferase reporter construct
might not require the co-recruitment of NCoA protein
pairs via the PAS-B domain or transcriptional activation
can be achieved through the recruitment of diﬀerent
coactivator complexes. In contrast, the stable overexpres-
sion of the NCoA-1 or NCoA-3 PAS-B domain inﬂuences
the expression of the endogenous AR target gene PSA,
which was postulated to display the co-recruitment of
NCoA protein pairs (35), in diﬀerent ways (Figure 5B).
While the PAS-B domain fragment of NCoA-1 enhanced
the expression of PSA, the NCoA-3 PAS-B domain
fragment diminished transactivation. Although we could
not ﬁnally elucidate which step in the coactivator assembly
is modiﬁed, these results are probably a consequence of an
aﬀected coactivator recruitment and altered coactivator
complex formation (data not shown).
Taken together our results demonstrate for the ﬁrst time
that NCoA proteins are able to interact via the PAS-B
domain and the CID/AD1. This allows intermolecular
interactions, possibly regulated through post-translational
modiﬁcations. These interactions obviously inﬂuence the
formation and recruitment of coactivator complexes to
promoter regions and thereby aﬀect the transcriptional
activation process. Our data suggest a new and comple-
mentary mechanism of the current model for the recruit-
ment of NCoA proteins. We postulate two dynamic
models of coactivator recruitment for the STAT6 and
steroid hormone receptor mediated transcriptional activa-
tion (Figure 6). First, the interplay between the PAS-B
domain and the CID/AD1 of NCoA proteins allows
intermolecular and potentially also intramolecular inter-
actions. The contact of the NCoA-1 PAS-B domain to
the STAT6 LXXLL motif abolishes these interactions.
Simultaneously, interaction of p300/CBP and the NCoA-1
CID/AD1 stabilizes the contact of STAT6 and p300/CBP
(61) (Figure 6A). The second model comprises the steroid
hormone receptor mediated transcriptional activation and
is based on the postulated recruitment of NCoA protein
Figure 6. Models for the recruitment of NCoA proteins. (A) Model
for the STAT6-mediated recruitment of NCoA-1. The contact of the
PAS-B domain of NCoA-1 to the STAT6 LXXLL motif abolishes the
intermolecular interaction of two NCoA-1 proteins. Interaction of
p300/CBP with NCoA-1 stabilizes the contact of p300/CBP with
STAT6 and enables transcriptional activation. (B) Model for the
recruitment of pairs of NCoA proteins to steroid hormone receptor
(SR) target gene promoters. The postulated co-recruitment of pairs of
NCoA-1 and NCoA-3 is mediated through the PAS-B domain and the
CID/AD1.
1858 Nucleic Acids Research, 2008, Vol. 36, No. 6pairs to speciﬁc target gene promoters of the estrogen
receptor and androgen receptor (35). In this model, the
co-recruitment of two NCoA proteins is achieved through
the interaction of the PAS-B domain and the CID/AD1
(Figure 6B). The postulated dimerization through the
aminoterminal bHLH/PAS domain could not be detected
in this work and therefore does not play a role in our
model. Further structural analysis of the NCoA-1 PAS-B/
CID/AD1 complex, which is currently underway, will help
us to understand conformational changes involved in
coactivator recruitment.
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